OBJECTIVE: To assess whether alterations in the stromal cell-derived factor-1 (SDF-1)/CXCR4 occur in patients with primary myelofibrosis (PMF) and in Gata1 low mice, an animal model for myelofibrosis, and whether these abnormalities might account for increased stem/progenitor cell trafficking. MATERIALS AND METHODS: In the mouse, SDF-1 mRNA levels were assayed in liver, spleen, and marrow. SDF-1 protein levels were quantified in plasma and marrow and CXCR4 mRNA and protein levels were evaluated on stem/progenitor cells and megakaryocytes purified from the marrow. SDF-1 protein levels were also evaluated in plasma and in marrow biopsy specimens obtained from normal donors and PMF patients. RESULTS: In Gata1 low mice, the plasma SDF-1 protein was five times higher than normal in younger animals. Furthermore, SDF-1 immunostaining of marrow sections progressively increased with age. Similar abnormalities were observed in PMF patients. In fact, plasma SDF-1 levels in PMF patients were significantly higher (by twofold) than normal (p < 0.01) and SDF-1 immunostaining of marrow biopsy specimens demonstrated increased SDF-1 deposition in specific areas. In two of the patients, SDF-1 deposition was normalized by curative therapy with allogenic stem cell transplantation. Similar to what already has been reported for PMF patients, the marrow from Gata1 low mice contained fewer CXCR4 pos CD117 pos cells and these cells expressed low levels of CXCR4 mRNA and protein. CONCLUSION: Similar abnormalities in the SDF-1/CXCR4 axis are observed in PMF patients and in the Gata1 low mice model of myelofibrosis. We suggest that these abnormalities contribute to the increased stem/progenitor cell trafficking observed in this mouse model as well as patients with PMF.
OBJECTIVE: To assess whether alterations in the stromal cell-derived factor-1 (SDF-1)/CXCR4 occur in patients with primary myelofibrosis (PMF) and in Gata1 low mice, an animal model for myelofibrosis, and whether these abnormalities might account for increased stem/progenitor cell trafficking. MATERIALS AND METHODS: In the mouse, SDF-1 mRNA levels were assayed in liver, spleen, and marrow. SDF-1 protein levels were quantified in plasma and marrow and CXCR4 mRNA and protein levels were evaluated on stem/progenitor cells and megakaryocytes purified from the marrow. SDF-1 protein levels were also evaluated in plasma and in marrow biopsy specimens obtained from normal donors and PMF patients. RESULTS: In Gata1 low mice, the plasma SDF-1 protein was five times higher than normal in younger animals. Furthermore, SDF-1 immunostaining of marrow sections progressively increased with age. Similar abnormalities were observed in PMF patients. In fact, plasma SDF-1 levels in PMF patients were significantly higher (by twofold) than normal (p < 0.01) and SDF-1 immunostaining of marrow biopsy specimens demonstrated increased SDF-1 deposition in specific areas. In two of the patients, SDF-1 deposition was normalized by curative therapy with allogenic stem cell transplantation. Similar to what already has been reported for PMF patients, the marrow from Gata1 low mice contained fewer CXCR4 pos CD117 pos cells and these cells expressed low levels of CXCR4 mRNA and protein. CONCLUSION: Similar abnormalities in the SDF-1/CXCR4 axis are observed in PMF patients and in the Gata1 low mice model of myelofibrosis. We suggest that these abnormalities contribute to the increased stem/progenitor cell trafficking observed in this mouse model as well as patients with PMF.
Authors: T Ponomaryov; A Peled; I Petit; R S Taichman; L Habler; J Sandbank; F Arenzana-Seisdedos; A Magerus; A Caruz; N Fujii; A Nagler; M Lahav; M Szyper-Kravitz; D Zipori; T Lapidot Journal: J Clin Invest Date: 2000-12 Impact factor: 14.808
Authors: K Hattori; B Heissig; K Tashiro; T Honjo; M Tateno; J H Shieh; N R Hackett; M S Quitoriano; R G Crystal; S Rafii; M A Moore Journal: Blood Date: 2001-06-01 Impact factor: 22.113
Authors: G A McQuibban; G S Butler; J H Gong; L Bendall; C Power; I Clark-Lewis; C M Overall Journal: J Biol Chem Date: 2001-09-24 Impact factor: 5.157
Authors: Stefan O Ciurea; Delwin Merchant; Nadim Mahmud; Takefumi Ishii; Yan Zhao; Wenyang Hu; Edward Bruno; Giovanni Barosi; Mingjiang Xu; Ronald Hoffman Journal: Blood Date: 2007-05-01 Impact factor: 22.113
Authors: Maria Verrucci; Alessandro Pancrazzi; Miguel Aracil; Fabrizio Martelli; Paola Guglielmelli; Maria Zingariello; Barbara Ghinassi; Emanuela D'Amore; José Jimeno; Alessandro M Vannucchi; Anna Rita Migliaccio Journal: J Cell Physiol Date: 2010-11 Impact factor: 6.384
Authors: Te Ling; John D Crispino; Maria Zingariello; Fabrizio Martelli; Anna Rita Migliaccio Journal: Expert Rev Hematol Date: 2018-02-19 Impact factor: 2.929
Authors: Anna Rita Migliaccio; Fabrizio Martelli; Maria Verrucci; Massimo Sanchez; Mauro Valeri; Giovanni Migliaccio; Alessandro Maria Vannucchi; Maria Zingariello; Angela Di Baldassarre; Barbara Ghinassi; Rosa Alba Rana; Yvette van Hensbergen; Willem E Fibbe Journal: Blood Date: 2009-07-01 Impact factor: 22.113
Authors: Eva Zetterberg; Maria Verrucci; Fabrizio Martelli; Maria Zingariello; Laura Sancillo; Emanuela D'Amore; Rosa Alba Rana; Anna Rita Migliaccio Journal: Platelets Date: 2013-10-31 Impact factor: 3.862
Authors: Christina Hart; Sabine Klatt; Johann Barop; Gunnar Müller; Roland Schelker; Ernst Holler; Elisabeth Huber; Wolfgang Herr; Jochen Grassinger Journal: Haematologica Date: 2016-08-04 Impact factor: 9.941